HDAC9 and intrahepatic cholangiocarcinoma: These data are directly translatable, and in the context of limited survival outcomes for patients with this disease, an early phase prospective study combining FGFR and HDAC inhibition for patients with FGFR2 fusion-positive ICC is justified.